Myo-inositol in a new pharmaceutical form: A step forward to a broader clinical use

Expert Opinion on Drug Delivery

Volumn 9, Issue 3, 2012, Pages 267-271

  Carlomagno, Gianfranco ^a   De Grazia, Sara ^a   Unfer, Vittorio ^a   Manna, Fedele ^b  

^a AGUNCO Obstet and Gynecol Ctr   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bioavailability; Myo inositol; PCOS; Pharmacokinetics; PMDD; Psychiatric disorders; Soft gelatin capsules

Indexed keywords

GELATIN; INOSITOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POWDER; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSULES; FEMALE; GELATIN; HUMANS; INOSITOL; MALE; POWDERS; YOUNG ADULT;

EID: 84857531074     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.662953     Document Type: Article

References (17)

1. Agranoff BW. Turtles all the way: reflections on myo-Inositol. J Biol Chem 2009;284(32):21121-6
2. Balla T. Phosphoinositide-derived messengers in endocrine signaling. J Endocrinol 2006;188(2):135-53 (Pubitemid 43273804)
3. Balla T. Inositol-lipid binding motifs: signal integrators through protein-lipid and protein-protein interactions. J Cell Sci 2005;118(Pt 10):2093-104 (Pubitemid 40872833)
4. Halet G, Tunwell R, Balla T, et al. The dynamics of plasma membrane PtdIns(4,5)P(2) at fertilization of mouse eggs. J Cell Sci 2002;115(Pt 10):2139-49 (Pubitemid 34746380)
5. Papaleo E, Unfer V, Baillargeon JP, et al. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009;147(2):120-3
6. Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci 2011;15:931-6
7. Gullapalli RP. Soft gelatin capsules (softgels). J Pharm Sci 2010;99(10):4107-48
8. Carlomagno G, Unfer V, Buffo S, et al. Myo-inositol in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 2011;26(7):526-30
9. Unfer V, Carlomagno G, dante G, et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012. [Epub ahead of print]
10. Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91(5):1750-4
11. Ciotta L, Stracquadanio M, Pagano I, et al. Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci 2011;15(5):509-14
12. Benjamin J, Levine J, Fux M, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995;152(7):1084-6
13. Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry 1995;152(5):792-4
14. Lissy M, Scallion R, Stiff DD, et al. Pharmacokinetic comparison of an oral diclofenac potassium liquid-filled soft gelatin capsule with a diclofenac potassium tablet. Expert Opin Pharmacother 2010;11(5):701-8
15. Saano V, Paronen P, Peura P, et al. Relative pharmacokinetics of three oral 400 mg ibuprofen dosage forms in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1991;29(10):381-5
16. Curtis JJ, Barbeito R, Pirsch J, et al. Differences in bioavailability between oral cyclosporine formulations in maintenance renal transplant patients. Am J Kidney Dis 1999;34(5):869-74 (Pubitemid 29521703)
17. Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm 2009;72(1):105-10